Propofol or Sevoflurane

Phase 3Small molecule

MMatthew Borzage

Propofol or Sevoflurane is one of 7 small molecule programs targeting Hemodynamic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemodynamicRecruiting

HemodynamicPhase 3

Recruiting

Competition

Competitive Landscape

8 competitors in Hemodynamic

#DrugCompanyPhaseTrials

Gnrh Ant

Merck & Co.

Phase 3

1 2

Propofol or Sevoflurane

MMatthew Borzage

Phase 3

1 3

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 4

Diphenhydramine Hcl

Roche

Preclinical

1 5

Crystalloid

KKonkuk University Medical Center

Preclinical

1 6

Urapidil

UUniversity Hospital, Strasbourg, France

Preclinical

1 7

Colloid

SSahlgrenska University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemodynamic1 trial

Individual Cerebral Hemodynamic Oxygenation Relationships

Recruiting·MMatthew Borzage·Phase 4·NCT04435834·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Propofol or Sevoflurane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Propofol or Sevoflurane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Propofol or Sevoflurane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Matthew Borzage company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMatthew Borzage

Propofol or Sevoflurane

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemodynamic1 trial

References

Drug Info

Quick Facts

Related News